Skip to content
Screener

Integra LifeSciences IART Other Non-Current Assets

Other Non-Current Assets at other companies

Axogen logo
AxogenAXGN
$729K
Globus Medical logo
Globus MedicalGMED
$79.24M+5.9%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$1.65M+1,012%
MiMedx Group logo
MiMedx GroupMDXG
$11.9M+1,102%
Medtronic logo
MedtronicMDT
$4.15B+15.7%
Organogenesis Holdings Inc. logo
Organogenesis Holdings Inc.ORGO
$22.93M+163%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.34B+35.1%
Enterprise value$3.09B+15.4%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:DefinedBenefitPlanFairValueOfPlanAssets.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058

The estimated fair values of plan assets were $69.7 million and $71.7 million as of June 30, 2026 and December 31, 2025, respectively. The net plan assets of the pension plans are invested in common trusts as of June 30, 2026 and December 31, 2025. Common trusts are classified as Level 2 in the fair value hierarchy. The fair value of common trusts is valued at the net asset value based on the fair values of the underlying investments of the trusts as determined by the sponsor of the trusts. The investment strategy of the Company’s defined benefit plans is both to meet the liabilities of the plans as they fall due and to maximize the return on invested assets within an appropriate risk profile.

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's other non-current assets?
Integra LifeSciences (IART) reported other non-current assets of $69.7M in Q2 2026.
How has Integra LifeSciences's other non-current assets changed year-over-year?
Integra LifeSciences's other non-current assets increased by 16.6% year-over-year, from $59.8M to $69.7M.
What is the long-term trend for Integra LifeSciences's other non-current assets?
Over 5 years (2020 to 2025), Integra LifeSciences's other non-current assets has grown at a 27.4% compound annual growth rate (CAGR), from $11.28M to $37.88M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.

Ask your AI about Integra LifeSciences's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude